Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation.
R. Gijtenbeek (Leeuwarden, Netherlands), K. De Jong (Leeuwarden, Netherlands), B. Venmans (Leeuwarden, Netherlands), F. Van Vollenhoven (Leeuwarden, Netherlands), A. Van Der Wekken (Groningen, Netherlands), W. Van Geffen (Leeuwarden, Netherlands)
Source: International Congress 2022 – Identification of therapeutic strategies in lung cancer
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Gijtenbeek (Leeuwarden, Netherlands), K. De Jong (Leeuwarden, Netherlands), B. Venmans (Leeuwarden, Netherlands), F. Van Vollenhoven (Leeuwarden, Netherlands), A. Van Der Wekken (Groningen, Netherlands), W. Van Geffen (Leeuwarden, Netherlands). Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation.. 1930
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|